First Covishield jab triggers ‘good levels’ of antibodies | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Sunday
June 29, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SUNDAY, JUNE 29, 2025
First Covishield jab triggers ‘good levels’ of antibodies

Coronavirus chronicle

TBS Report
22 May, 2021, 06:05 pm
Last modified: 22 May, 2021, 06:10 pm

Related News

  • Serum Institute, Bill Gates get Bombay high court notice as petitioner claims Covishield killed his daughter
  • India gives conditional market nod for Covishield and Covaxin
  • Denmark to offer fourth coronavirus jab while easing curbs
  • Indian man, 84, says he took 12 jabs; govt disputes claim
  • UK says 4th Covid jabs not needed for now as booster effect lasts

First Covishield jab triggers ‘good levels’ of antibodies

The current vaccine regimen calls for a four- to six-week interval between two doses of Covaxin. However, the government recently increased the time between two doses for Covishield from six to eight weeks to 12-16 weeks

TBS Report
22 May, 2021, 06:05 pm
Last modified: 22 May, 2021, 06:10 pm
Balram Bhargava, Director General, ICMR   -  VV Krishnan via The Hindu Business Line
Balram Bhargava, Director General, ICMR - VV Krishnan via The Hindu Business Line

Balram Bhargava, director-general of the Indian Council of Medical Research (ICMR) said, "good levels" of antibodies are formed in the body after the first dose of Covishield vaccine.

However, with Covaxin adequate immune response is activated only after the second dose, he added, reports The Hindu Business Line. 

Bhargava was responding to a query about the new ICMR protocol on the time between two vaccine doses at the weekly Covid update media briefing. 

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The decision to increase the time between two Covishield doses was based on observations from three committees, according to Bhargava, the Covid Working Group, the National Expert Group on Vaccine Administration for Covid-19 (NEGVAC), and the National Technical Advisory Group on Immunisation.

The current vaccine regimen calls for a four- to six-week interval between two doses of Covaxin. However, the government recently increased the time between two doses for Covishield from six to eight weeks to 12-16 weeks.

"Vaccines first came on December 15. We are very new and are learning; trials are still on. It is an evolving science. By giving the first dose of Covaxin, you do not achieve much of antibodies, you achieve it after the second dose. With Covishield, antibodies are achieved at good levels," Bhargava said.

This also puts pressure on manufacturers of Covaxin to make vaccines available for the second dose. Bharat Biotech, manufacturers of Covaxin, is in the process of commencing production in facilities in Kolar, Karnataka and Manjari near Pune, besides Hyderabad. The Covaxin technology has also been transferred to three public sector enterprises, including Indian Immunologicals Limited (IIL), a Hyderabad-based subsidiary of the National Dairy Development Board.

25 lakh tests by month end

At the briefing, Bhargava also spoke about testing facilities. He said the government aims to conduct 25 lakh tests by the end of the month and 45 lakh tests by June. He urged people to go for more rapid antigen tests so that the spread can be prevented by adopting measures like isolation. He said the pace of tests needs to be speeded up till the 5 per cent positivity rate is achieved. "For home testing for Covid-19, three companies are in the pipeline for approval," Bhargava added.

Lav Agarwal, Joint Secretary, Health Ministry, said eight States have reported more than one lakh active cases, in nine States, they are in the 50,000-100,000 range and 19 States have less than 50,000 active cases. Karnataka and West Bengal remain a concern, with more than 25 per cent positivity rate. Tamil Nadu and some north-eastern States have been asked to continue with containment measures, he added.

Agarwal further stated that since the last nine days, the number of recovered cases has actually surpassed the active cases. He said 69 per cent of the total active cases are limited to only eight States compared with 21 States, where the recovered cases are more than the daily registered ones.

Mucormycosis, an epidemic

On the Centre notifying Mucormycosis as an epidemic, Agarwal said, every case has to be reported by the hospital to the public health network. All the guidelines related to its treatment and management have to be followed, he added.

Top News / World+Biz

Covishield / jab / 'good levels' / anitbodies

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Return to work or face stern action, govt warns protesters as NBR jobs declared 'essential services'
    Return to work or face stern action, govt warns protesters as NBR jobs declared 'essential services'
  • Officials of the NBR, under the banner of the NBR Unity Council, continued their protest on Sunday since 9am. Photo: Syed Zakir Hossain/TBS
    NBR stalemate: Finance adviser to meet business leaders today, no talks with protesting officials
  • Photo: TBS
    Govt amends criminal procedure to prevent harassment in false cases: Asif Nazrul

MOST VIEWED

  • Biman Bangladesh bans WhatsApp for official use
    Biman Bangladesh bans WhatsApp for official use
  • How ONE Bank hides Tk995cr loss through provision deferral
    How ONE Bank hides Tk995cr loss through provision deferral
  • File photo of containers at Chattogram port/TBS
    Complete NBR shutdown halts customs operations, Chattogram Port paralysed
  • Infograph: TBS
    How banks made record profits in a depressed year
  • A battery-operated three-wheeled e-rickshaw on display at the inauguration ceremony of a driver training programme at the Dhaka North City Corporation auditorium on 28 June 2025. Photo: TBS
    E-rickshaws to be introduced in Uttara, Dhanmondi, Paltan areas in August
  • File photo of Umama Fatema/Collected
    'All of us were only deceived': Umama Fatema steps down from Students Against Discrimination

Related News

  • Serum Institute, Bill Gates get Bombay high court notice as petitioner claims Covishield killed his daughter
  • India gives conditional market nod for Covishield and Covaxin
  • Denmark to offer fourth coronavirus jab while easing curbs
  • Indian man, 84, says he took 12 jabs; govt disputes claim
  • UK says 4th Covid jabs not needed for now as booster effect lasts

Features

Photo: Collected

Innovative storage accessories you’ll love

1h | Brands
Two competitors in this segment — one a flashy newcomer, the other a hybrid veteran — are going head-to-head: the GAC GS3 Emzoom and the Toyota CH-R. PHOTOS: Nafirul Haq (GAC Emzoom) and Akif Hamid (Toyota CH-R)

GAC Emzoom vs Toyota CH-R: The battle of tech vs trust

1h | Wheels
How a young man's commitment to nature in Tetulia won him a national award

How a young man's commitment to nature in Tetulia won him a national award

19h | Panorama
From blossoms to bounty: The mango season that revives Rajshahi

From blossoms to bounty: The mango season that revives Rajshahi

19h | Panorama

More Videos from TBS

July Uprising anniversary: What’s NCP planning?

July Uprising anniversary: What’s NCP planning?

1h | TBS Today
NTRCA office surrounded

NTRCA office surrounded

1h | TBS Today
Who is ahead in nuclear weapons?

Who is ahead in nuclear weapons?

1h | Others
SC stays verdict on service discipline rules for lower court judges

SC stays verdict on service discipline rules for lower court judges

2h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net